A large observational study led by researchers at nference suggests that reaching higher doses of semaglutide (Wegovy) may be linked to a lower incidence of certain neuropsychiatric and neurological conditions, independent of how much weight a patient loses. The findings, published in npj Metabolic Health and Disease, analyse thousands of medical histories to explore whether drug dose or weight loss better predicts subsequent brain-related diagnoses.
Semaglutide is part of the GLP-1 receptor agonist family, originally developed to help manage blood sugar in type 2 diabetes and later largely adopted as an obesity treatment. Beyond metabolic effects, the drugs interact with GLP-1 receptors found in the brain, including regions tied to appetite and reward, prompting scientists to investigate potential brain-wide benefits of higher dosing.
The study, undertaken by Karthik Murugadoss and Venky Soundararajan of nference, used a sizeable electronic health record database to track outcomes over two years. It began with 63,215 patients prescribed semaglutide who also had a documented history of a neurological or psychiatric condition, and compared them with a matched group taking metformin to control for factors such as age, sex, body mass index, and diabetes status.
Over a two-year follow-up, those on semaglutide generally exhibited lower rates of newly diagnosed neuropsychiatric issues than those on metformin. For example, substance-related disorders appeared in 3.8 per cent of the semaglutide group versus 6.1 per cent in the metformin group, while mood disorders were documented in 10.5 per cent of semaglutide users compared with 13.2 per cent of metformin users.
To probe the relationship further, the researchers split semaglutide patients by the maximum dose reached in the first two years and by the maximum weight loss achieved in the same period, then examined subsequent neuropsychiatric diagnoses in the following two years. The landmark approach allowed them to test whether dose and weight loss independently related to outcomes.
Achieving a higher maximum dose—defined as 1.7 milligrams or more—was associated with notably lower rates of several mental health conditions than staying on a lower dose of 0.25 to 1.0 milligrams. Those on high doses had a 29 per cent lower relative risk of developing substance-related disorders and an 18 per cent lower relative risk of mood disorders. Similar reductions were observed for anxiety, neuromuscular diseases and impulse-control disorders.
“Where dose and weight loss appear to diverge is telling,” Soundararajan explained. “Whether changing someone’s dose would produce those differences requires a randomized control trial.” He also noted that the dose-related benefits did not extend across all neurological outcomes, with dementia or degenerative CNS disease showing no significant difference between dose groups.
When patients were grouped by how much weight they lost, ranging from under 5 per cent to more than 20 per cent, the same pattern did not emerge. The authors concluded that the psychiatric benefits linked with semaglutide did not appear to be driven simply by weight loss.
“The weighing scale may tell only part of the story when it comes to GLP-1 medicines,” Soundararajan said. “Higher attained Wegovy doses were associated with fewer subsequent mood, anxiety-related and substance-related diagnoses, without corresponding differences across weight-loss groups. This raises an important question for future research: how much can weight change alone tell us about a patient’s broader neuropsychiatric health improvement response to treatment?”
There was one notable exception: cognitive and speech symptoms. These outcomes tended to track with weight loss rather than dose, with cognitive symptoms rising slightly from 2.1 per cent in the group with the least weight loss to 4.7 per cent among those who shed the most weight. The researchers caution that extreme weight loss in real-world data can reflect underlying health declines, which could account for the uptick in cognitive issues rather than any direct drug effect.
For biological context, the team also consulted public genetic data to map where the GLP-1 receptor is produced in the human brain. They found trace levels in regions such as the hypothalamus and the caudate nucleus, a finding the authors say provides a plausible route for direct central nervous system interaction.
As with all retrospective work, the study carries caveats. The authors emphasise that the results cannot establish causation and acknowledge healthy-adherer bias—the possibility that patients tolerating higher doses or maintaining treatment are healthier or more engaged with care. Diagnostic codes in medical records also lag behind real-world onset of conditions, and the work does not address immediate psychiatric side effects that might occur soon after initiating treatment. The authors stress that the findings should not be used to justify prescribing semaglutide specifically for psychiatric conditions.
“Independent of weight loss should be understood cautiously: comparing separate dose and weight-loss groups does not establish a direct drug effect independent of weight,” Soundararajan noted. “People who reach higher doses may differ in treatment tolerance, continuity of care and affordability, all of which could influence outcomes. We measured newly recorded diagnoses, which cannot establish recovery from an existing mental-health condition.”
Looking ahead, the researchers say the goal is to identify which patients stand to benefit, at what dose, and with what trade-offs across bodily systems, with plans to apply AI-assisted review of clinical notes to better understand actual medication use and symptom trajectories. They aim to test the signals in prospective, gold-standard trials to validate real-world findings.
For patients living with obesity or diabetes who also face mental-health challenges, the researchers conclude, everyday functioning and emotional well-being are central to the idea of better health. They hope the study prompts future research that measures treatment success in ways that reflect those priorities.
The study, titled Higher semaglutide dose is associated with lower neuropsychiatric event incidence independent of weight loss, was authored by Karthik Murugadoss, A. J. Venkatakrishnan, and Venky Soundararajan.
